Edgewise Therapeutics
Breanne Newell-Stamper's work experience includes:
- Scientist II at Edgewise Therapeutics since May 2021. No end date provided.
- Scientist I at Edgewise Therapeutics from October 2019 to May 2021.
- Research Scientist Apprentice at Edgewise Therapeutics from January 2018 to October 2019. The role focused on surgical procedures, muscle isolation, characterization of muscle forces, development of high-throughput automated systems, and behavior testing for general and neuromuscular health.
- Instructor at the University of Colorado Boulder's Pre-Collegiate Development Program from June 2017 to July 2018.
Breanne Newell-Stamper's education history begins in 2007 when they enrolled at the University of Colorado Boulder to pursue a Bachelor of Arts (B.A.) degree in Integrative Physiology (IPHY). Breanne completed their undergraduate studies in 2012.
Following their bachelor's degree, Breanne continued their education at the University of Colorado Boulder. From 2012 to 2014, they pursued a Master of Science (M.S.) degree in Integrative Physiology.
In 2012, while still a student at the University of Colorado Boulder, Breanne also joined the Institute for Behavioral Genetics as a Pre-Doctoral Trainee. Breanne held this position until 2018.
During their time at the Institute for Behavioral Genetics, Breanne concurrently attended the Institute of Behavioral Science as a Pre-Doctoral Trainee from 2017 to 2018.
Finally, in 2015, Breanne began their journey towards a Doctor of Philosophy (PhD) degree in Integrative Physiology at the University of Colorado Boulder. Breanne completed their PhD studies in 2018.
This summarizes Breanne Newell-Stamper's education history based on the provided information.
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.